Top-Rated StocksTop-RatedNASDAQ:VKTX Viking Therapeutics (VKTX) Stock Price, News & Analysis $34.03 +0.05 (+0.15%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$34.40 +0.37 (+1.09%) As of 04:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Viking Therapeutics Stock (NASDAQ:VKTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Viking Therapeutics alerts:Sign Up Key Stats Today's Range$33.50▼$34.7350-Day Range$24.86▼$34.4252-Week Range$18.92▼$81.73Volume2.70 million shsAverage Volume3.96 million shsMarket Capitalization$3.83 billionP/E RatioN/ADividend YieldN/APrice Target$86.92Consensus RatingBuy Company Overview Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Read More Viking Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreVKTX MarketRank™: Viking Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 396th out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingViking Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageViking Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Viking Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Viking Therapeutics are expected to decrease in the coming year, from ($1.56) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viking Therapeutics is -22.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viking Therapeutics is -22.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViking Therapeutics has a P/B Ratio of 4.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Viking Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.44% of the outstanding shares of Viking Therapeutics have been sold short.Short Interest Ratio / Days to CoverViking Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Viking Therapeutics has recently increased by 88,996.57%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViking Therapeutics does not currently pay a dividend.Dividend GrowthViking Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.88 Percentage of Shares Shorted25.44% of the outstanding shares of Viking Therapeutics have been sold short.Short Interest Ratio / Days to CoverViking Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Viking Therapeutics has recently increased by 88,996.57%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.48 News SentimentViking Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Viking Therapeutics this week, compared to 16 articles on an average week.Search Interest53 people have searched for VKTX on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.MarketBeat FollowsOnly 27 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Viking Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $984,405.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Viking Therapeutics is held by insiders.Percentage Held by Institutions76.03% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Viking Therapeutics' insider trading history. Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Stock News Headlines2 Beaten-Down Stocks With Incredible Upside PotentialAugust 3 at 12:32 PM | fool.com2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top AnalystsAugust 3 at 6:00 AM | fool.com[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells… | Goldco Precious Metals (Ad)Viking Therapeutics, Inc. (NASDAQ:VKTX) Short Interest Up 88,996.6% in JulyAugust 3 at 2:58 AM | americanbankingnews.comIs Viking Therapeutics the Next Big Biotech Bet?August 1, 2025 | fool.comViking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 TrialJuly 31, 2025 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 TrialJuly 31, 2025 | insidermonkey.comBrokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Target Price at $86.92July 29, 2025 | americanbankingnews.comSee More Headlines VKTX Stock Analysis - Frequently Asked Questions How have VKTX shares performed this year? Viking Therapeutics' stock was trading at $40.24 at the beginning of the year. Since then, VKTX stock has decreased by 15.4% and is now trading at $34.03. How were Viking Therapeutics' earnings last quarter? Viking Therapeutics, Inc. (NASDAQ:VKTX) issued its quarterly earnings results on Wednesday, July, 23rd. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.14. The business's revenue was up NaN% on a year-over-year basis. Read the conference call transcript. When did Viking Therapeutics IPO? Viking Therapeutics (VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager. Who are Viking Therapeutics' major shareholders? Top institutional investors of Viking Therapeutics include Bank of New York Mellon Corp (0.39%), Blair William & Co. IL (0.29%), Simplex Trading LLC and Profit Investment Management LLC (0.10%). Insiders that own company stock include Brian Lian, Marianna Mancini, Greg Zante, Lawson Macartney, Charles A Rowland Jr, J Matthew Singleton and Sarah Kathryn Rouan. View institutional ownership trends. How do I buy shares of Viking Therapeutics? Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Viking Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viking Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Invesco QQQ (QQQ), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD). Company Calendar Last Earnings7/23/2025Today8/05/2025Next Earnings (Estimated)10/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VKTX CIK1607678 Webwww.vikingtherapeutics.com Phone(858) 704-4660FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Viking Therapeutics$86.92 High Price Target$138.00 Low Price Target$30.00 Potential Upside/Downside+155.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$109.96 million Net MarginsN/A Pretax MarginN/A Return on Equity-19.98% Return on Assets-19.38% Debt Debt-to-Equity RatioN/A Current Ratio25.86 Quick Ratio25.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.90 per share Price / Book4.31Miscellaneous Outstanding Shares112,440,000Free Float107,835,000Market Cap$3.83 billion OptionableOptionable Beta0.67 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:VKTX) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.